Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2012 Jul 19;12(8):564-71. doi: 10.1038/nrc3278.

NRF2 and cancer: the good, the bad and the importance of context.

Author information

1
Department of Pharmacology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA. e-michael.sporn@dartmouth.edu

Abstract

Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.

PMID:
22810811
PMCID:
PMC3836441
DOI:
10.1038/nrc3278
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center